Orphan drug designation: US FDA and Saudi Arabia
A plain explanation for patients, families and doctors, checked against the regulator's own pages on 17 October 2026.
Reviewed by the Reserve Meds clinical operations team on 17 October 2026. Sources accessed 17 October 2026.
The short answer
Orphan drug designation is a status FDA gives a drug or biologic intended for a rare disease. It qualifies the company for incentives such as tax credits for clinical trials, exemption from user fees and potentially seven years of market exclusivity after approval. It is separate from approval: designated drugs still need full FDA review. Saudi Arabia now has its own orphan designation.
- US regulator: FDA Office of Orphan Products Development.
- What it is: A designation, not an approval.
- US incentives: Tax credits, user fee exemption, potential seven-year exclusivity.
- Saudi Arabia: SFDA Rare Diseases framework, in force from 5 September 2026.
What orphan designation is in the US
FDA can grant orphan drug designation to a drug or biological product to prevent, diagnose or treat a rare disease or condition. Sponsors must submit a request, and a sponsor seeking designation for the same drug and disease as a previously designated product must submit its own data.[1]
Designation is separate from seeking approval or licensing. Drugs for rare diseases go through the same rigorous scientific review as any other drug. FDA's Orphan Drug Designations and Approvals database lists designated products.[1]
Incentives for the company
- Tax credits for qualified clinical trials.[1]
- Exemption from FDA user fees.[1]
- Potential seven years of market exclusivity after approval.[1]
These incentives exist because rare-disease medicines serve small numbers of patients and might otherwise not be developed.
Saudi Arabia's own orphan designation
The SFDA issued a Regulatory Framework for Rare Diseases Drugs in August 2026, in force from 5 September 2026. We give you a written timeline estimate for your case before you commit. For unregistered rare-disease medicines, it points to the Named Patient Program and the Special Access Program.[2]
What designation means for a family
A US orphan designation tells you a company is developing a drug for a rare disease. It does not mean the drug is approved or available. Check the US approval status on Drugs@FDA before planning any request.
If the drug is FDA-approved but not registered in your country, the treating hospital can ask the regulator for a named-patient or special access import, and we can coordinate US supply once approval is in place.[3, 4]
Orphan designation and other expedited programs
Orphan designation is often combined with other programs. A rare-disease drug may also have Fast Track or Breakthrough Therapy designation during development, receive priority review, and, for a rare pediatric disease, qualify the company for a priority review voucher.[5, 6, 7, 8]
Questions to ask the treating specialist
- Is the medicine only designated, or actually approved, and for exactly which patients?
- Is it registered in our country? If not, will the hospital request it under the Named Patient or Special Access Program?
- Are there tests the label requires before treatment?
- What follow-up and monitoring will be needed after treatment starts?
How Reserve Meds helps
Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help families and treating doctors understand the route, prepare the documents the regulator or hospital asks for, arrange supply from the US once approval is in place, and keep everyone updated. We do not diagnose, prescribe or decide what a regulator approves.
We coordinate access to FDA-approved medicines only. Investigational medicines are only available through a manufacturer's expanded-access program requested by the treating physician; we can explain that route, but we do not supply them. Your coordination fee is quoted in writing for your case before you commit. No hidden charges. We give you a written timeline estimate for your case before you commit.
Ask us whether a medicine can reach your patient
Tell us the medicine, your country and a WhatsApp or phone number. We reply within one business day. On WhatsApp we usually reply the same day.
Frequently asked questions
Does orphan drug designation mean a drug is approved?
No. It is a separate status that gives the company incentives. The drug still needs full FDA review before approval.
What incentives come with US orphan designation?
Tax credits for qualified clinical trials, exemption from user fees, and potentially seven years of market exclusivity after approval.
Does Saudi Arabia have orphan drug designation?
Yes. The SFDA Regulatory Framework for Rare Diseases Drugs, in force from 5 September 2026, offers orphan designation for diseases affecting fewer than 1 in 2,000 people in Saudi Arabia.
How can a family in Saudi Arabia get an FDA-approved rare-disease medicine that is not registered?
Through the treating hospital, using the SFDA Named Patient Program or Special Access Program that the rare disease framework points to.
Sources for these answers: [1, 2]
Sources
All sources were opened and checked on 17 October 2026. Rules and labels change, so the treating hospital or regulator confirms the current position before anything is filed.
- US FDA: Designating an Orphan Product, Drugs and Biological Products (accessed 17 October 2026)
- SFDA: Regulatory Framework for Rare Diseases Drugs, version 1.0 (August 2026) (accessed 17 October 2026)
- US FDA: How do I find out if a drug is approved? (accessed 17 October 2026)
- SFDA: Special Access Program (SAP) guidance, version 1.0 (accessed 17 October 2026)
- US FDA: Fast Track (information for patients) (accessed 17 October 2026)
- US FDA: Breakthrough Therapy (accessed 17 October 2026)
- US FDA: Priority Review (information for patients) (accessed 17 October 2026)
- US FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs (2026 update) (accessed 17 October 2026)
Related
- Rare pediatric disease designation
- EU exceptional circumstances
- All access pathways
- US expanded access (compassionate use)
- Named-patient access, explained
- Answers to common access questions
This page is general information, not medical or legal advice. It does not replace advice from your own doctor or the regulator.